Envoy Medical's Fully Implanted Cochlear Implant Shows 38-Point Speech Gain at 12 Months
COCH has more than doubled off its 52-week low of $0.363 on light trading volume (0.4× avg).
Summary
Envoy Medical reported 12-month data from the first 10 patients in its pivotal Acclaim cochlear implant trial, showing mean CNC word recognition scores improved to 53.2% from a 15.2% baseline — a 38 percentage point gain that builds on the 24-point improvement at 6 months. Nine of 10 patients responded, with a mean score of 59.1% when excluding one potential non-responder. No serious adverse events were reported. This marks completion of Stage 1 primary endpoint follow-up; Stage 2 is fully enrolled with 12-month data expected by early Q2 2027, followed by a PMA submission. The results strengthen the case for a first-of-its-kind fully implanted device, though the company still faces going concern risk and a sub-$1 stock price. The data de-risks the regulatory path and could attract partnership or financing interest ahead of the PMA filing.
At the time of this announcement, COCH was trading at $0.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.3M. The 52-week trading range was $0.36 to $1.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: TMX Newsfile.